Drug Discovery World

FEBRUARY 2, 2023

A team of experts from the University of Glasgow will lead a new international effort to improve cancer control and reduce global health inequalities. The post Commission tackles global access to precision cancer treatments appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment International Clinical Trials Science 130

Drug Discovery World

FEBRUARY 16, 2023

Minoryx Therapeutics has revealed the findings from the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients. Treatment with leriglitazone also significantly reduced plasma levels of MMP-9, a marker of blood-brain barrier integrity.

Treatment 130

Treatment Disease Clinical Trials International 130

Drug Discovery World

NOVEMBER 17, 2023

Arcellx entered a global strategic collaboration with Kite Pharma in December 2022 to co-develop and co-commercialise CART-ddBCMA for the treatment of this patient group. Just 38 patients were evaluable for efficacy and safety analysis in June 2023 based on a median follow-up of 22 months following treatment.

Trials 130

Trials International Therapies Treatment 130

Drug Discovery World

JUNE 1, 2023

Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France, and Italy. Current treatment of neuropathic pain is dominated by anti-epileptic medicines, antidepressants, and traditional painkillers, none of which provide any long-term pain alleviation.

Trials 130

Trials Small Molecule Drugs Pharmaceuticals 130

Drug Discovery World

DECEMBER 8, 2022

A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes. . The results were presented at the International Diabetes Federation (IDF) World Diabetes Congress 2022. .

Trials 130

Trials Medical Schools Clinical Trials International 130

Drug Discovery World

MARCH 13, 2023

LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The post LEO partners with ICON to offer patient-centric dermatology trials appeared first on Drug Discovery World (DDW).

Trials 130

Trials Clinical Trials Laboratories Clinical Development 130

Drug Discovery World

OCTOBER 1, 2024

Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. P-BCMA-ALLO1 is an investigational non-viral, stem cell memory T cell (TSCM)-rich allogeneic CAR-T cell therapy.

Therapies 147

Therapies Trials FDA Approval Clinical Trials 147

Drug Discovery World

DECEMBER 13, 2022

Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have reported in The Lancet. . Clinical trial details.

Treatment 130

Treatment Clinical Trials Laboratories Therapies 130

Drug Discovery World

FEBRUARY 9, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC). versus 11.5%).

Treatment 130

Treatment Clinical Research International FDA 130

Drug Discovery World

MARCH 16, 2023

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML. International Journal of Molecular Science, 21(4): 1537. Around one third of patients with AML are diagnosed with FLT3-mutations, which are associated with a higher risk of relapse and poor clinical outcome. and Leung, A. and Wang, H-G.

Treatment 130

Treatment FDA FDA Approval Drug Development 130

Drug Discovery World

DECEMBER 6, 2022

Myeloma Patients Europe (MPE) has launched an advocacy report on addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE). . The MPE report presents clinical trial analytics, looking at the number of clinical trials held in CEE countries between 1 January 2001 and 28 September 2020.

Clinical Trials 130

Clinical Trials Trials Nurses International 130

Conversations in Drug Development Trends

AUGUST 9, 2024

Authors: Matt Cooper, PhD, Executive Director, Therapeutic Strategy Lead, Oncology; Megan Morrison, Vice President, Asia Pacific Strategy Lead Adaptive trial designs have become essential in oncology, offering a flexible and efficient approach for conducting clinical trials.

Trials 80

Trials Clinical Trials Regulations FDA 80

SCIENMAG: Medicine & Health

JUNE 15, 2023

A new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options. Credit: Vanderbilt University Medical Center A new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

Treatment 83

Treatment Clinical Trials International Therapies 83

Drug Discovery World

OCTOBER 9, 2023

Positive Phase I trial data indicates that Reqorsa (quaratusugene ozeplasmid) has shown early efficacy for the treatment of non-small cell lung cancer (NSCLC). The data will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Therapies 277

Therapies Clinical Trials Trials International 277

Drug Discovery World

JULY 19, 2023

52% of participants completed their course of treatment by one year and 72% completed by 18 months as a result of achieving plaque clearance. “We are extremely pleased that donanemab yielded positive clinical results with compelling statistical significance for people with Alzheimer’s disease in this trial.

Disease 130

Disease Trials Clinical Trials Therapies 130

Advarra

OCTOBER 1, 2024

Managing clinical trial budgets efficiently is necessary for the success and sustainability of clinical research sites. Effective budget management not only ensures trials are financially viable but also maximizes return on investment (ROI). the impact and value of the data produced).

Clinical Trials 52

Clinical Trials Trials Compliance Laboratories 52

Alta Sciences

SEPTEMBER 13, 2023

Four Pain Models Altasciences Uses to Assess Treatments During Clinical Trials pmjackson Wed, 09/13/2023 - 17:01 September is pain awareness month, and the importance of pain management and continued research into effective analgesics is integral to helping patients suffering from various pain conditions.

Clinical Trials 52

Clinical Trials Treatment Trials Drug Development 52

Drug Discovery World

JANUARY 30, 2023

Dominic Elliston , Managing Director of Evoke Galliard and Evoke Incisive Health, shares his take on how effective clinical trial communications is the key to expediting the delivery of new and extraordinary treatments. What’s that got to do with clinical trials? Tell us about yourself, Dominic. Can you give us an example?

Clinical Trials 130

Clinical Trials Trials Clinical Development International 130

Conversations in Drug Development Trends

APRIL 3, 2024

By: Sue Batchelor, Executive Director, Oncology Project Management Radiopharmaceuticals represent a cutting-edge frontier in oncology treatment, offering the promise of highly targeted therapy with the potential to revolutionize cancer care. Are you aware of the challenges you must address for a successful radiopharmaceutical trial?

Trials 81

Trials Clinical Trials Compliance Treatment 81

Drug Discovery World

JUNE 27, 2024

Novo Nordisk has announced results from the Phase III FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment with the investigational treatment Mim8. for once-monthly treatment.

FDA Approval 147

FDA Approval Trials Treatment Hospitals 147

Common Sense for Drug Policy Blog

APRIL 21, 2024

Agonist Treatment for Cannabis Use Disorder "Cannabinoid agonist treatment is unlikely to be an approach relevant to all cannabis users seeking treatment, as evidenced by the large numbers of individuals who did not complete the study screening process, and the modest 12-week treatment retention rates. JAMA Intern Med.

Treatment 52

Treatment Clinical Trials International Therapies 52

Drug Discovery World

SEPTEMBER 27, 2024

The efficacy of the treatment was evaluated in the IMROZ trial in patients with newly diagnosed multiple myeloma who were not eligible for ASCT. The main efficacy outcome measure was progression-free survival (PFS) as assessed by an independent review committee based on International Myeloma Working Group criteria.

FDA Approval 130

FDA Approval FDA International Treatment 130

Drug Discovery World

NOVEMBER 28, 2023

An international team of scientists has shown that a stem cell therapy for multiple sclerosis (MS) could prevent further damage to the brain. The early-stage clinical trial was the result of a collaboration between researchers at University of Colorado Anschutz Campus, the University of Cambridge and the University of Milano-Bicocca. “We

Therapies 264

Therapies Clinical Trials Trials Treatment 264

Drug Discovery World

MAY 8, 2024

The ORCA-V1 trial was led by Achieve Life Sciences, and co-led by an investigator from Massachusetts General Hospital. “No In their previous clinical trial, the research team found that cytisinicline helped people to quit smoking traditional cigarettes. “The For cytisinicline treatment compared to placebo, 31.8% versus 15.1%

Clinical Trials 182

Clinical Trials Compliance Trials Drugs 182

Drug Discovery World

MAY 10, 2024

A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas.

Drugs 173

Drugs Trials Therapies International 173

Conversations in Drug Development Trends

JANUARY 24, 2024

Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment. One diagnostic example that I discussed in my presentation is autism.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Drug Discovery World

AUGUST 6, 2024

Centogene has announced data from its Rostock International Parkinson’s Disease (ROPAD) Study revealing the genetic factors and prevalence of Parkinson’s disease (PD). The findings from the study indicate that approximately 15% of PD-related cases are tied to genetic variants, with the majority being linked to LRRK2 and GBA1.

Clinical Trials 162

Clinical Trials Disease International Trials 162

H1 Blog

SEPTEMBER 26, 2023

Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. Additionally, clinical trials are no longer confined to one country or region.

Trials 59

Trials Clinical Trials International Regulations 59

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel Phase II trial incorporating Hu14.18 A novel Phase II trial incorporating Hu14.18

Licensing 246

Licensing Licensing Hospitals Therapies 246

Drug Discovery World

AUGUST 24, 2022

A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments. . The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment.

Research 246

Research Clinical Trials Virus Trials 246

Drug Discovery World

SEPTEMBER 19, 2024

P-BCMA-ALLO1 is an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase I/Ib clinical development for the treatment of patients with relapsed/refractory multiple myeloma.

Therapies 130

Therapies FDA Clinical Development International 130

Drug Discovery World

MAY 10, 2024

Study 008A Study 008A was a four-week, international, randomised, double-blind and placebo-controlled add-on Phase II/III study performed in 45 centres in 11 countries in Europe, Asia and Latin America. 291 patients were randomised to treatment either with evenamide or placebo as add-on to their current antipsychotic therapy.

International 182

International Pharmaceuticals Treatment Trials 182

Drug Discovery World

JULY 5, 2024

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS). Furthermore, by acting at the site of pathology, evenamide might also be effective for negative symptoms and cognitive dysfunction.”

Pharmaceuticals 264

Pharmaceuticals Clinical Development International Therapies 264

PPD

OCTOBER 9, 2023

“Patient-centric” is used frequently to describe today’s clinical trial and health care landscape. The industry applauds that point of view and strives to include a patient-centric approach in all aspects of clinical trial designs. Patient centricity has become more than a key consideration.

Clinical Trials 98

Clinical Trials Trials Compliance International 98

PPD

JUNE 7, 2023

As therapies for the treatment of NASH in adult patients go this year to the U.S. Food and Drug Administration (FDA) for approval , much work remains for drug developers aiming to advance treatments for pediatric populations. Partnership with an experienced CRO is essential to your trial’s success. Hispanic: 11.8%

Trials 98

Trials Clinical Trials Clinical Research Disease 98

Drug Discovery World

JULY 30, 2024

In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language and decision-making by nearly 50% compared to placebo. The trial data was reported at the Alzheimer’s Association International Conference (AAIC) 2024, in Philadelphia, US.

Trials 130

Trials Clinical Trials Disease Science 130

Drug Discovery World

NOVEMBER 3, 2023

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

Clinical Trials 130

Clinical Trials Drugs Trials Therapies 130